semaglutide johnstown co Now enrolling for GLP-1 medical weight support with licensed provider oversight Semaglutide

Clinical evidence SELECT cardiovascular outcomes SELECT enrolled 17,604 adults aged 45 years with established atherosclerotic cardiovascular disease (prior MI, stroke, or symptomatic peripheral arterial disease) and BMI 27 kg/m, but without diabetes, randomizing them 1:1 to semaglutide 2.4 mg SC weekly (after titration) or placebo on top of standard CV therapies

Patients should be aware that GLP-1 medications are initiated and monitored within specialist or primary care diabetes services

Staying within personal use boundaries and avoiding commercial activity or medical claims keeps researchers on the right side of these boundaries

Philipp J Sci 151:813821

Compounded semaglutide from licensed 503A pharmacies can be prepared at multiple strengths to support this step-wise titration safely